Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Voluntarily sign written informed consent.~* Male or non-pregnant and non-lactating females.~* Confirmed diagnosis (by endoscopy procedure) of active, mild to moderate UP or UPS, with disease extending at least 5 centimeters (cm) but no further than 40 cm from the anal verge.~* Must possess a baseline Modified Mayo Disease Activity Index (MMDAI) score between 5 and 10.~Exclusion Criteria:~* History or current diagnosis of Crohn's disease and indeterminate colitis.~* Prior gastrointestinal surgery except appendectomy and hernia.~* Concomitant active gastrointestinal disease or distortion of intestinal anatomy.~* History of diverticulitis, collagenous colitis, celiac disease, recurrent pancreatic or known gallbladder disease.~* Uncontrolled, previously diagnosed type 1 or 2 diabetes mellitus.~* Uncontrolled abnormal thyroid function.~* Unstable significant cardiovascular, endocrine, neurologic or pulmonary disease.~* Hemoglobin levels less than (\<) 7.5 grams /deciliter (g/dL).~* History of sclerosing cholangitis, cirrhosis, or hepatic impairment.~* Renal disease manifested by greater than (\>) 2.0 milligrams/deciliter (mg/dL) serum creatinine.~* History of avascular hip necrosis, active tuberculosis, ocular herpes simplex or ocular varicella zoster, malignant disease, and human immunodeficiency virus (HIV) or hepatitis B or C.~* Adrenal insufficiency.~* Active systemic or cutaneous infection or toxic megacolon, fistula, perforation or abscess.~* History of uncontrolled psychiatric disorders or seizure disorders.~* History of asthma requiring ongoing use of inhaled steroids.~* Recent history of drug or alcohol abuse.~* Positive stool test for bacterial pathogens, Clostridium difficile toxin, or ovum and parasites.~* Vaccination within 28 days prior to randomization.~* Allergies to budesonide or to any other items used in its preparation.~* Participation in another clinical trial in the past 30 days.~* Pregnant or at risk of pregnancy.~* Taking a prohibited medication. Some medications to treat UP/UPS are prohibited during participation in the study, including laxatives and anti-diarrhea medications; however, oral 5-ASA agents at doses up to 4.8 g/day and daily fiber supplements are allowed. Other medications (e.g., antibiotics, anti-seizure and anti-coagulant medicines) are also prohibited.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Budesonide (Type: EXPERIMENTAL): Participants who were diagnosed with active mild to moderate UP or UPS, will receive 2 milligrams (mg)/25 milliliter (mL) of budesonide foam, rectally twice daily for a period of 2 weeks followed by 2 mg/25 mL of budesonide foam, rectally once daily for a period of 4 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Participants who were diagnosed with active mild to moderate UP or UPS will receive 25 mL of placebo matching to budesonide foam twice daily for a period of 2 weeks followed by once daily for a period of 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete